Related Experiment Video
Updated: Jan 20, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Rituximab as Rescue Therapy for Aggressive Pediatric Multiple Sclerosis
George Vartzelis1, Despoina Maritsi1, Maria Nikolaidou1
1Second Department of Pediatrics, National and Kapodistrian University of Athens, Medical School, "P. & A. Kyriakous" Children's Hospital, Athens, Greece.
Insights
Rituximab offers a promising treatment for pediatric multiple sclerosis (MS). This therapy effectively induced remission in a young boy with severe, treatment-refractory MS.
Area of Science:
- Neurology
- Immunology
- Pediatrics
Background:
- Multiple sclerosis (MS) is a chronic neurological disease with limited pediatric treatment options.
- Pediatric MS affects nearly 10% of MS patients, necessitating effective therapies.
- Rituximab, an anti-CD20 antibody, depletes CD20+ lymphocytes and is an emerging therapy.
Abstract:
Multiple sclerosis is a chronic, debilitating disease. Almost one in ten patients with MS has a history of disease onset during childhood. Although numerous therapeutic options exist for adult MS, the available treatments for pediatric patients are still limited. One of the emerging therapies is rituximab, a monoclonal anti-CD20 chimeric antibody that can deplete the CD20+ lymphocyte populations. A 12-year-old boy presented with ataxia, paresthesias, and headache while his brain MRI showed numerous T2 contrast-enhancing lesions. Gamma globulin, steroids, and cyclophosphamide failed to intercept his disease, and he progressed to a rapid clinical and radiological deterioration. Treatment with rituximab reversed the disease course in a dramatic fashion, leading to complete remission.
Related Concept Videos
Aggression
Secondary Motives: Affiliation Motivation and Aggression Motivation
Gene Therapy
Multiple Allele Traits
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution

